Antibiotics in acute exacerbations of COPD: the good, the bad and the ugly.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Non-Pharmaceutical Techniques for Obstructive Airway Clearance Focusing on the Role of Oscillating Positive Expiratory Pressure (OPEP): A Narrative Review.Pulmonary therapy · 2022
   Review
2. Virus-induced Volatile Organic Compounds Are Detectable in Exhaled Breath during Pulmonary Infection.American journal of respiratory and critical care medicine · 2021
   Article
3. Predicting treatment outcomes following an exacerbation of airways disease.PloS one · 2021
   Observational
4. Impact and prevention of severe exacerbations of COPD: a review of the evidence.International journal of chronic obstructive pulmonary disease · 2017
   Review
5. Is 'GOLD' standard for the management of COPD in clinical practice?Drugs in context · 2012
   Article

Corrections and comments

• Comment on
  Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results.2012

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as